STUDY QUESTION: Does a breast cancer diagnosis impact ovarian function in the setting of fertility preservation?
Introduction
An estimated 246 660 women in the United States will have been diagnosed with breast cancer in 2016 (American Cancer Society, 2016) .
Eleven percent of breast cancers occur in individuals younger than 45 years of age (United States National Institutes of Health, 2016) . Advances in diagnostic tools and treatments have led to improvements in survival: 88.4% of women diagnosed with breast cancer prior to age 45 will survive at least 5 years (United States National Institutes of Health, 2016) . However, breast cancer treatment may impact future fertility, particularly when treatment involves gonadotoxic chemotherapy or a delay in attempting conception to accommodate treatment (Letourneau et al., 2012) .
While technological advancements have made fertility preservation possible for cancer patients, there are conflicting data regarding the expected response to ovarian stimulation for fertility preservation in this population. Male patients with malignancy have been noted to have decreased quality and quantity of sperm even prior to treatment (Shekarriz et al., 1995; Agarwal et al., 1996; Hallak et al., 2000; Rueffer et al., 2001; Sieniawski et al., 2008) . This observation has prompted investigations into the impact of a cancer diagnosis on gonadal function in females.
While some reports have suggested a lesser response to ovarian stimulation in cancer patients when compared to controls (Pal et al., 1998; Klock et al., 2010; Domingo et al., 2012; Friedler et al., 2012) , others have refuted this (Knopman et al., 2009; Noyes et al., 2010; Quintero et al., 2010; Das et al., 2011; Almog et al, 2012; GarciaVelasco et al, 2013; Johnson et al., 2013) . Intra-follicular estrogen is instrumental in follicular growth and oocyte development in animals (Zelinski-Wooten et al., 1993) ; thus, it can be proposed the lower estradiol levels, due to use of aromatase inhibitors during ovarian stimulation in patients with hormone-sensitive cancers, may explain a reduced response to ovarian stimulation in cancer patients compared to controls. However, reports have been inconsistent: one study demonstrated that patients with hormone-sensitive cancers who used aromatase inhibitors during ovarian stimulation had fewer total and mature oocytes retrieved when compared to those with hormonereceptor negative cancers (Domingo et al., 2012) while others reported equivalent outcomes in cancer patients with and without aromatase inhibitor administration (Vizcaino et al., 2012; Cakmak et al., 2013) . Contrasting results to date may be explained by small study populations, lack of controlling for individual differences in ovarian reserve, variations in treatment protocols in cases as compared to controls, and the selection of infertile controls.
Researchers have also suggested that cancer patients do not have a poorer response to ovarian stimulation, but, rather, a limited ovarian reserve, as assessed by anti-mullerian hormone level (AMH) or antral follicle count (AFC) (Lawrenz et al., 2012) . This hypothesis is based upon the corollary association of a diagnosis of cancer with a decrease in quantity and quality of sperm. However, AMH and AFC are imperfect markers of true ovarian reserve. Ovarian suppression due to use of oral contraceptives, for example, has been shown to reduce AMH and AFC by 10-50% and thus may lead to an underestimation of ovarian reserve (Bentzen et al., 2012; Dolleman et al., 2013; Kallio et al., 2013; Birch Petersen et al., 2015) . Cancer patients are more likely to be on oral contraceptives at the time of diagnosis compared to infertility patients. Thus, cancer patients with recent oral contraceptive use may be inaccurately perceived to have decreased ovarian reserve as compared to infertile patients, as AMH and AFC may not accurately reflect true ovarian reserve in this population.
In this study, we sought to evaluate ovarian reserve and response to ovarian stimulation in patients newly diagnosed with breast cancer by comparing them to an appropriate control population: healthy patients undergoing elective oocyte cryopreservation.
Materials and Methods

Study population
The cohort undergoing fertility preservation for breast cancer included all 191 patients treated at the University of California, San Francisco Center for Reproductive Health between 2009 and 2015 who had a recent breast cancer diagnosis, no prior history of infertility, and planned treatment with the potential to compromise future fertility. Breast cancer patients undergoing fertility preservation were divided into two groups: those with estrogen-sensitive tumors using the aromatase inhibitor, letrozole, during stimulation and those without estrogen-sensitive tumors. Elective oocyte cryopreservation was performed in 398 women with no history of infertility during the same time frame. Only first cycles for both cohorts were included. Approval was obtained from the University of California, San Francisco Committee on Human Research.
Ovarian stimulation protocols
In both study and control cohorts, ovarian stimulation was performed with a GnRH antagonist protocol. The starting dose and adjustment of gonadotropins were based on the clinic's standard of care. The initial dosage of gonadotropins (Follistim, Merck; Gonal-F, EMD-Serono; and/or Menopur, Ferring) was determined by the patient's age, her BMI and ovarian reserve, as estimated by AFC, measured on the day of initial consultation. Gonadotropin dosages were adjusted based on estradiol levels and follicle count/size to maximize response while minimizing the risk of ovarian hyperstimulation syndrome (OHSS). Estradiol level was assessed at every clinic visit during ovarian stimulation. GnRH antagonist (0.25 mg Ganirelix acetate, Organon or 0.25 mg Cetrotide, EMD-Serono) was administered daily to prevent premature ovulation when the lead follicle measured ≥12 mm mean diameter.
All elective fertility preservation patients and breast cancer patients presenting around the start of menses underwent conventional start ovarian stimulation with initiation of gonadotropins on Day 2 of their menstrual cycle. For breast cancer patients who did not present at menses (n = 104), random-start ovarian stimulation was performed as described in a prior publication from our center (Cakmak et al, 2013) .
For patients with estrogen-sensitive breast cancer, 5 mg letrozole was administered daily beginning with the start of ovarian stimulation and titrated up to as much as 10 mg per day with the goal of maintaining estradiol levels close to that observed during mono-follicular development in natural cycles (<500 pg/mL). The final dose of letrozole was taken the evening of trigger injection.
Final oocyte maturation was induced with hCG (5000 or 10 000 IU subcutaneously) or GnRH agonist (4 mg leuprolide acetate subcutaneously) trigger injection depending upon size of the follicular cohort and perceived risk of OHSS. The trigger injection was administered when the largest follicle attained a mean diameter of 18 mm with the general cohort of follicles >13 mm. If letrozole was used, the criteria for trigger was a follicle reaching a mean diameter of 20 mm with a general cohort of follicles >13 mm (Oktay et al, 2006) .
Oocyte retrieval was performed under transvaginal ultrasound guidance 36 h after hCG or GnRH agonist administration. Cumulus cells were stripped 2-3 h after retrieval and oocyte cryopreservation was performed by slow freeze or vitrification according to the laboratory standard at the time. For patients desiring embryo cryopreservation, ICSI was performed with ejaculated sperm in MII oocytes. Embryos were cryopreserved on either day three or day five depending upon the quality and quantity of embryos in a given cohort.
Outcome measures
The primary outcome measure was mature (MII) oocytes retrieved. Secondary outcome measures included AFC, days of stimulation, total dose of gonadotropins, peak serum estradiol, follicles measuring ≥13 mm on day of trigger, oocytes retrieved, oocyte maturity rate (MII/total oocytes retrieved), mature oocyte yield (MII/AFC) and fertilization rate (2PN/MII).
Statistical analysis
Initial comparison of continuous outcomes of subjects undergoing fertility preservation in the setting of a breast cancer diagnosis and those pursuing elective cryopreservation was performed by t-test. Subsequently, subjects with a breast cancer diagnosis were divided into two groups based upon the presence of estrogen-sensitive disease and the associated use of letrozole during stimulation. Continuous outcomes between these two groups of patients with breast cancer and the third group undergoing elective cryopreservation were compared with ANCOVA, with co-variates of age, BMI and total gonadotropin dose. For dichotomous outcomes, a chi-squared test was employed. A linear regression was performed to identify predictors of ovarian stimulation outcome. An ANOVA was performed to compare predictors of ovarian reserve by breast cancer stage. In a final analysis, subjects with estrogen-sensitive tumors were divided into three groups based upon their maximum letrozole dose and ANCOVA was performed with covariates of age and BMI. Statistical significance was defined as P < 0.05. Stata 14.0 software (Statacorp; College Station, TX) was used for analysis.
Results
Ovarian reserve, as measured by AFC, is not impacted by a breast cancer diagnosis
Of 191 women with a recent breast cancer diagnosis, 151 had estrogen-sensitive tumors and took letrozole during stimulation, while 40 did not. There were 171 women who had cancer stage information available, 34.5% (n = 59) were Stage 1, 50.9% (n = 87) were Stage 2 and 14.6% (n = 25) were Stage 3 or 4.
Patients undergoing breast cancer-related fertility preservation were younger (34.9 ± 4.6 vs 36.4 ± 3.0 years, P < 0.001) and had an increased mean BMI (23.6 ± 4.6 vs 22.8 ± 3.4 kg/m 2 , P = 0.019) compared to those pursuing elective cryopreservation (n = 398, see Table I ). Baseline AFC was no different between patients with breast cancer and those undergoing elective fertility preservation (15.4 ± 10.4 vs 15.4 ± 10.0; Table I) even after categorizing the patients by age (Table II) . Furthermore, among patients with breast cancer with staging information available, AFC did not vary with disease severity (Supplementary Table SI) .
Ovarian response to stimulation and oocyte yield are similar in breast cancer patients and those undergoing elective fertility preservation All patients underwent ovarian stimulation using a GnRH antagonist for pituitary suppression. The cycle characteristics are shown in Table III . There was no difference between breast cancer patients and controls with respect to use of GnRH agonist trigger injection (10.8% cancer vs 16.8% elective). In an ANCOVA model controlled for age, BMI, total gonadotropin dose and letrozole use, there was no difference in the number of total (19.4 ± 0.9 vs 17.0 ± 0.5) or mature (MII) oocytes retrieved (13.7 ± 0.7 vs 13.2 ± 0.4) between patients with breast cancer and those undergoing elective fertility preservation (Supplementary Table SII) .
Elective fertility preservation patients were more likely to have their cycle canceled due to poor response than patients undergoing fertility preservation in the setting of a breast cancer diagnosis (9.6 vs 4.7%, P = 0.043). For those who proceeded to retrieval, there was no difference in the likelihood of retrieving six oocytes or fewer between patients with breast cancer and those undergoing elective fertility preservation (Table IV) . In order to investigate whether a subgroup of breast cancer patients with more severe disease performed differently from the cohort, a multivariate linear regression model was performed and confirmed that stage of disease was not predictive of ovarian stimulation outcome as measured by mature oocyte yield (data not shown). 18-34 years 18.3 ± 13.5 (n = 81) 19.1 ± 11.8 (n = 83) NS 35-37 years 16.0 ± 9.5 (n = 188) 14.7 ± 8.2 (n = 42) NS 38-40 years 13.3 ± 7.4 (n = 101) 11.4 ± 8.1 (n = 45) NS 40-42 years 11.1 ± 6.6 (n = 23) 10.0 ± 7.4 (n = 18) NS ≥43 years 10.2 ± 4.9 (n = 5) 10.3 ± 3.8 (n = 3) NS a t-test.
Data presented as mean ± SD. AFC: antral follicle count.
Use of letrozole in breast cancer patients with estrogen-sensitive disease does not affect ovarian stimulation outcomes
Breast cancer patients with estrogen-sensitive tumors were administered an aromatase inhibitor, letrozole, daily to maintain low estrogen levels during ovarian stimulation. Patients who used letrozole had longer ovarian stimulation cycles compared to women undergoing elective fertility preservation but had similar cycle length cycles to cancer patients not using letrozole (Table III) . Breast cancer patients (both letrozole and no letrozole groups) used higher daily doses of gonadotropins (Table III) . Patients who used letrozole had more follicles measuring ≥13 mm on the day of trigger injection and lower peak estradiol levels compared to women undergoing elective fertility preservation (Table III) . While patients using letrozole had higher numbers of total oocytes retrieved compared to the elective fertility preservation group, there was no difference in the number of MII oocytes or the mature oocyte yield (MII/AFC) . The maturity rate (MII/total oocytes) was lower in breast cancer patients using letrozole compared to those undergoing elective cryopreservation, but similar to breast cancer patients without letrozole use (Table IV) . Breast cancer patients using letrozole had a similar fertilization rate compared to cancer patients without letrozole (0.76 ± 0.02 vs 0.85 ± 0.02). For patients with estrogen-sensitive tumors, it is our center's practice to uptitrate the dose of letrozole with the goal of maintaining estradiol levels close to that observed during mono-follicular development in natural cycles (<500 pg/mL). Given the finding of decreased maturity rate in our cancer population using letrozole, we sought to determine whether letrozole uptitration affected cycle outcome. In an analysis controlled for age and BMI, there was no significant difference in maturity or fertilization rates based upon the maximum letrozole dose (Supplementary Table SIII ).
Discussion
We demonstrate that patients with newly diagnosed breast cancer do not have compromised ovarian reserve. Additionally, we show that these patients have a similar response to ovarian stimulation with equivalent ovarian stimulation outcomes to patients undergoing elective fertility preservation. Finally, we provide comparative laboratory outcomes for a large cohort of patients with estrogen-receptor positive breast cancer who used letrozole during ovarian stimulation for fertility preservation and demonstrate similar outcomes to the cohort undergoing elective cryopreservation and those undergoing fertility preservation for estrogen-receptor negative breast cancer.
In males, malignancy has been associated with decreased quality and quantity of sperm even prior to treatment (Shekarriz et al., 1995; Agarwal et al., 1996; Hallak et al., 2000; Rueffer et al., 2001; Sieniawski et al., 2008) . This is hypothesized to occur as a result of either direct damage to germinal epithelium by immune-mediated injury or disruption of hypothalamic-pituitary-gonadal axis via elevated cytokines (Meirow and Schenker, 1995; Rueffer et al., 2001 ). In addition, some studies have demonstrated a direct association between cancer stage and degree of abnormality of semen analysis (Rueffer et al., 2001) while others have not (Shekarriz et al., 1995) . In female patients with cancer, it has been similarly hypothesized that malignancy, through increased catabolic state and malnutrition or stress-induced hypothalamic dysfunction, may affect ovarian reserve, follicle development, and quality of oocytes (Schenker et al., 1992; Agarwal and Said, 2004) .
Previous studies have failed to report baseline ovarian reserve assessments in cancer patients and controls (Garcia-Velasco et al., 2013) . Without this information, it is difficult to determine if divergent outcomes between the two groups are related to differences in ovarian reserve or response to stimulation. Lawrenz et al. addressed this question by measuring basal AMH level in 38 patients with lymphoma prior to chemotherapy as compared to 38 age-matched controls undergoing infertility treatment and found a lower ovarian reserve in the cancer patients (Vizcaino et al., 2012) . As previously discussed, ovarian reserve markers may not accurately represent primordial follicle count. It is possible that the lymphoma patients in this study were more likely to have a recent history of oral contraceptive use when compared to their age-matched infertile controls and thus their AMH may not accurately reflect their primordial follicular pool. We found no difference in AFC between breast cancer patients and those undergoing elective fertility preservation in a much larger sample size. Of note, elective fertility preservation patients are likely to have a similar history of recent oral contraceptive use when compared to agematched patients with a recent diagnosis of breast cancer and thus are a more appropriate control group. Additionally, we demonstrated that cancer stage did not have any impact on ovarian stimulation outcomes for the breast cancer patients in our cohort. This is consistent with our conclusion that breast cancer patients do not have evidence of compromised ovarian reserve prior to their gonadotoxic treatment.
Retrospective reviews of clinical outcomes of ovarian stimulation for fertility preservation in women with a cancer diagnosis have had conflicting results, with some demonstrating a poorer response in cancer patients (Pal et al., 1998; Klock et al., 2010; Domingo et al., 2012; Friedler et al., 2012) , while others have found no difference in comparison with controls (Knopman et al., 2009; Noyes et al., 2010; Quintero et al., 2010; Das et al., 2011; Almog et al., 2012; GarciaVelasco et al., 2013; Johnson et al., 2013) . Early reports suggesting impaired response to ovarian stimulation in cancer patients undergoing fertility preservation were limited by small sample sizes due to the relative novelty of the technique (Pal et al., 1998; Klock et al., 2010) . A subsequent meta-analysis of seven studies with a total of 218 cancer patients demonstrated decreased numbers of total and mature oocytes retrieved in cancer patients when compared to age-matched controls (Friedler et al., 2012) . Notably, this meta-analysis included heterogeneous studies with differing ovarian stimulation protocols and inclusion criteria. Furthermore, cancer patients underwent milder stimulation protocols than controls, which may explain decreased oocyte yield in the face of similar fertilization and cancellation rates. In contrast to these prior studies, we included a large population of breast cancer patients undergoing fertility preservation prior to gonadotoxic treatment from a single center using a GnRH antagonist protocol and found no difference in number of total or mature oocytes retrieved in breast cancer patients compared to healthy controls.
Prior studies on this topic utilized infertile patients as controls. Some studies used a control population consisting of patients with tubal factor infertility (Pal et al., 1998) , while several selected couples with male-factor infertility (Knopman et al., 2009; Das et al., 2011; Robertson et al., 2011; Almog et al., 2012; Domingo et al., 2012) , and yet others included a heterogeneous group of patients seen at infertility practice as controls (Klock et al., 2010; Quintero et al., 2010; Johnson et al., 2013) . Patients who have been attempting to achieve pregnancy unsuccessfully are clearly a different population from those undergoing fertility preservation. We included patients undergoing elective fertility preservation with no prior history of infertility as controls. To our knowledge, there is only one other study utilizing a control population undergoing fertility preservation for 'non-medical' indications (Garcia-Velasco et al., 2013) . In that report, the cancer patients were younger, had shorter stimulation cycles, higher cancellation rates, and a lower mature oocyte rate than controls. This study was limited by the use of disparate triggers in their comparison groups: all cancer patients received GnRH agonist for induction of final maturation while the controls received hCG. In contrast, using identical stimulation and trigger protocols, we demonstrate no difference in ovarian stimulation outcomes, including total and mature oocytes retrieved and mature oocyte yield, among breast cancer patients and elective fertility preservation controls.
Our breast cancer population using letrozole for estrogen-sensitive disease had an increased number of follicles ≥13 mm on the day of trigger and increased number of total oocytes retrieved. This can be explained by the disparate trigger criteria in letrozole-containing cycles: trigger injections were administered with a lead follicle of 20 mm in letrozole-based cycles while all other cycles were triggered with a lead follicle of 18 mm. This practice is based upon prior clinical data suggesting decreased oocyte maturity at equivalent mature-range follicle sizes (Oktay et al., 2006) . This phenomenon is explained by in vitro studies that have suggested that aromatase inhibitors alter follicular fluid dynamics by promoting early antral cavity formation (Hu et al., 2002) . It is notable that we did not find a statistically significant decrease in MII/follicle ≥13 mm in our breast cancer patients using letrozole. While the longer cycles in letrozole-based protocols yielded an increased number of total oocytes retrieved compared to elective cryopreservation, the number of MII oocytes was not statistically different, due to a decreased maturity rate. However, mature oocyte yield (MII/AFC) was not different between groups. Additionally, there was no significant difference in maturity or fertilization rate with increasing letrozole dose.
Although we have shown that breast cancer diagnosis is not associated with decreased ovarian reserve and response to stimulation when compared with patients undergoing elective fertility preservation the possibility remains that a subset of breast cancer patients, such as those harboring BRCA mutations, may have poorer fertility outcomes (Oktay et al., 2010) . This question needs to be addressed further.
Study strengths, limitations and future directions
Our study strengths include a large sample size of recently diagnosed breast cancer patients with no infertility history, an appropriate control population of patients undergoing elective fertility preservation, and similar ovarian stimulation protocols. Additionally, only first cycles were included, thereby avoiding bias related to repeat cycles. The study is limited by the absence of subsequent embryo and pregnancy data although previous reports of limited numbers of cancer patients returning to attempt pregnancy post-treatment have demonstrated reasonable pregnancy rates after thaw of previously vitrified oocytes and embryos (Garcia-Velasco et al., 2013; Druckenmiller et al., 2016) .
Additionally, many of our breast cancer patients underwent random start-ovarian stimulation to reduce risk of delay in treatment of their malignancy. While we have previously reported similar outcomes in conventional start and random-start ovarian stimulation protocols (Cakmak et al., 2013) , we have not routinely begun to use this protocol for our elective fertility preservation patients. While breast cancer patients may have undergone random-start ovarian stimulation, baseline ovarian reserve was defined by AFC on the initial day of consultation regardless of phase of the menstrual cycle for all patients. While some authors have suggested that AFC varies throughout the menstrual cycle (Deb et al., 2013) , others have argued that AFC remains relatively unchanged across the cycle (Rombauts et al., 2011) . Cancer patients and those desiring elective fertility preservation were equally likely to have this initial consultation and ovarian reserve assessment performed in the follicular phase. Thus, the similar age-adjusted AFC measurements are felt to represent equivalent ovarian reserve in these populations. A comparison of AMH values between breast cancer patients and those undergoing elective fertility preservation would further strengthen this claim.
Finally, many reproductive-aged women use contraceptive pills for contraception or menstrual dysfunction (Jones et al., 2012) . Recent long-term use of oral contraceptives has been associated with lower AFC and AMH (Bentzen et al., 2012; Dolleman et al., 2013; Kallio et al., 2013; Johnson et al., 2014; Petersen et al., 2015) . It could be hypothesized that elective cryopreservation patients may have the opportunity to delay ovarian stimulation for several months to allow for recovery from any suppression due to long-term use of hormonal contraceptives. Breast cancer patients undergoing cryopreservation prior to treatment would not have this opportunity. As a result, we might expect breast cancer patients to have inferior outcomes, yet this was not the case. Although we do not have information regarding recent oral contraceptive use in either population, this should be explored further.
Conclusion
Breast cancer diagnosis is not associated with a decrease in ovarian reserve, response to ovarian stimulation or oocyte yield when compared to a population undergoing elective oocyte cryopreservation. Furthermore, similar ovarian stimulation outcomes are demonstrated whether or not letrozole is used for estrogen-sensitive disease.
